Q-omics provides the consensus-scored MIR5192 profile across patient tissues and cancer cell-line models. MIR5192 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR5192 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, MIR5192 RNA expression shows 6,470 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BLCA, CHOL, and LAML as cancer lineages where MIR5192 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5192 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5192 survival associations across molecular data types. MIR5192 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5192 RNA expression–survival associations across cancer types. High MIR5192 expression shows unfavorable associations in BLCA, STAD, UCS, SKCM and LUSC, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR5192 RNA expression.
This table summarizes MIR5192 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5192. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5192 shows lower tumor expression in THCA and higher tumor expression in CHOL and BRCA. The CHOL box plot shows higher MIR5192 RNA expression in tumor versus normal tissue (log2 FC = +0.835, t-test p < 0.001).
This table shows molecular features associated with MIR5192 in patient tissues and cancer cell lines. In patient samples, MIR5192 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
